NASDAQ:ADXN Addex Therapeutics (ADXN) Stock Price, News & Analysis $5.66 -0.03 (-0.53%) As of 12:47 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesSEC FilingsTrendsBuy This Stock About Addex Therapeutics Stock (NASDAQ:ADXN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Addex Therapeutics alerts:Sign Up Key Stats Today's Range$5.67▼$5.7250-Day Range$5.13▼$6.9552-Week Range$5.04▼$12.05Volume1,654 shsAverage Volume4,872 shsMarket Capitalization$6.97 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry. The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease. Additional programs include ADX71149, an mGlu2 positive allosteric modulator being investigated for mood and anxiety disorders, and early-stage GABAB receptor modulators. Addex employs proprietary drug discovery platforms to optimize targeting, selectivity and pharmacokinetic profiles, advancing multiple candidates through preclinical and clinical stages. Addex Therapeutics serves global markets through strategic collaborations with pharmaceutical partners to co-develop and potentially commercialize its pipeline. The company’s integrated R&D operations in Europe and North America support translational research and clinical studies. Led by a management team with deep experience in neuroscience drug development, Addex seeks to bring innovative allosteric therapies to patients with debilitating neurological and psychiatric conditions.AI Generated. May Contain Errors. Read More Addex Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreADXN MarketRank™: Addex Therapeutics scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingAddex Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageAddex Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Addex Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Addex Therapeutics is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Addex Therapeutics is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAddex Therapeutics has a P/B Ratio of 1.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Addex Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.09% of the float of Addex Therapeutics has been sold short.Short Interest Ratio / Days to CoverAddex Therapeutics has a short interest ratio ("days to cover") of 0.51, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Addex Therapeutics has recently decreased by 39.03%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAddex Therapeutics does not currently pay a dividend.Dividend GrowthAddex Therapeutics does not have a long track record of dividend growth. News and Social MediaN/ANews SentimentN/A Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Addex Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders15.00% of the stock of Addex Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions16.14% of the stock of Addex Therapeutics is held by institutions.Read more about Addex Therapeutics' insider trading history. Receive ADXN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Addex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADXN Stock News HeadlinesHead-To-Head Comparison: BetterLife Pharma (OTCMKTS:BETRF) versus Addex Therapeutics (NASDAQ:ADXN)July 30, 2026 | americanbankingnews.comAddex Therapeutics: Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and WakefulnessJuly 8, 2026 | finanznachrichten.deHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.August 6 at 1:00 AM | Stansberry Research (Ad)Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and WakefulnessJuly 8, 2026 | finance.yahoo.comAddex Therapeutics Ltd (ADXN) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...June 25, 2026 | finance.yahoo.comAddex Therapeutics Ltd (ADXN) Q1 2026 Earnings Call TranscriptJune 25, 2026 | seekingalpha.comAddex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateJune 25, 2026 | globenewswire.comAddex Therapeutics Ltd ADXNJune 24, 2026 | morningstar.comMSee More Headlines ADXN Stock Analysis - Frequently Asked Questions How have ADXN shares performed this year? Addex Therapeutics' stock was trading at $7.72 at the beginning of the year. Since then, ADXN shares have decreased by 23.7% and is now trading at $5.89. How were Addex Therapeutics' earnings last quarter? Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) announced its quarterly earnings data on Friday, November, 22nd. The company reported ($2.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.40) by $1.37. Read the conference call transcript. When did Addex Therapeutics' stock split? Addex Therapeutics shares reverse split on the morning of Monday, October 23rd 2023.The 1-20 reverse split was announced on Monday, October 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Addex Therapeutics IPO? Addex Therapeutics (ADXN) raised $0 in an initial public offering on Wednesday, January 29th 2020. The company issued 1,925,532 shares at $0.00 per share. How do I buy shares of Addex Therapeutics? Shares of ADXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Addex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Addex Therapeutics investors own include Arista Networks (ANET), Adobe (ADBE), NVIDIA (NVDA), Broadcom (AVGO), GE Aerospace (GE), Vista Energy (VIST) and Arch Capital Group (ACGL). Company Calendar Last Earnings11/22/2024Today8/06/2026Next Earnings (Estimated)8/24/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (24m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 ADXN's financial health is in the Red zone, according to TradeSmith. ADXN has been in this zone for over 24 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ADXN CIK1574232 Webwww.addextherapeutics.com Phone011-41-22-884-1555Fax41-22-884-1556Employees30Year Founded2002Profitability EPS (Trailing Twelve Months)($5.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.12 million Net MarginsN/A Pretax Margin-19,126.31% Return on Equity-134.76% Return on Assets-106.00% Debt Debt-to-Equity RatioN/A Current Ratio0.97 Quick Ratio0.97 Sales & Book Value Annual Sales$29.97 thousand Price / Sales232.65 Cash FlowN/A Price / Cash FlowN/A Book Value$4.67 per share Price / Book1.21Miscellaneous Outstanding Shares1,232,000Free Float1,047,000Market Cap$6.97 million OptionableNot Optionable Beta1.50 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:ADXN) was last updated on 8/6/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...Porter & Company | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredWhite House Insider: “President Trump is Getting Backstabbed!”A high-level White House insider and lifelong friend of the Trump family recently went on camera with a warnin...Paradigm Press | SponsoredThis under $7 stock could be.Just one mile from SpaceX's launchpad sits a small company doing something SpaceX can't - and it still trades ...Freedom Financial | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Addex Therapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Addex Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
